Invisible Women - Sexy Snails

Good morning GFPs! Welcome to your weekly dose of doom…or is it? Every now and then, someone gets in touch to ask if I could be a bit more upbeat, because this newsletter depresses the hell out of them. Could I include some good news, they ask? Well, look, I would love to, but the problem is there often isn’t a lot of good news to go around. Although, considered from another perspective, every one of these newsletters is good news, because knowledge is power, my friend. See this tweet I was sent this week:

Yes, you could see that as a negative and in one way it very much is: yet another drug that doesn’t work as well for women, and of course I worry for Emma and all other women who have an illness for which we don’t yet have a female-effective treatment. On the other hand, Emma now knows enough to challenge her doctors for better treatment. And even beyond that individual approach, every gender data gap identified is a gender data gap we are one step closer to closing. So take heart, my GFPs! Yes, there is a lot of work to be done. But by making ourselves aware of what that work is, by sharing it with others, by challenging our doctors, our workplaces, our families and friends, we are fixing this every single day.

Plus, you know, there’s always the Poppy Pic of the Week 😘🐾

Also I’m too tired to be jolly this week. Maybe next week.

This week I’m giving you TWO data gaps for the price of one, you lucky things! MORE KNOWLEDGE!

First, up, I was really pleased to see that the 2001 small scale study which found that 80% of drugs that had been withdrawn for unacceptable side effects had worse effects in women (see IW, p.215) has, only 19 years later, been updated with a larger scale study. I guess like the viagra-vs-period-pain research (see IW p.230-1) before it, well, it’s only women, so no rush, eh?

I was less pleased by the findings, of course: “striking” sex differences in blood concentration and drug elimination times (pharmacokinetics) were were found for 88% of the drugs evaluated, and these sex differences were strongly correlated with the rate of adverse drug reactions in women, including nausea, depression, bleeding, seizures, severe weight gain, cardiac abnormalities and, well, death. Body weight was not found to explain this sex difference.

“This,” explained the researchers, “likely contributes to the near doubling of adverse drug reactions in female patients, raising the possibility that women are routinely overmedicated.” The trouble is, there are “thousands of drugs for which sex-stratified [pharmacokinetic] data are not publicly available.” So, as usual, we possibly have a huge problem, it’s just that because we haven’t collected data on women we have no idea how big that problem is.

But still, the first step to fixing the male bias in medicine is better data, so this is a huge step forward.

when u sex-disaggregate ur data…

vs when u don’t…

🤪

But wait, there’s more!

So that’s nice, isn’t it.

So yesterday the American Beefcake (the AB to me and you) got himself some swanky new earphones. And he would NOT SHUT UP ABOUT THEM. I wouldn’t have minded, except, well:

If anyone has found a solution to wireless earphones that even with the smallest silicone bud are TOO BIG for your ears, please let me know! I currently use AirPods which are the only ones that just about fit for me, though they do hurt if I have them in too long.

So last week, I revealed the VERY EXCITING NEWS that I had a leech named after me, a discovery from which I am still recovering. The revelation also struck a chord with another reader, who had this to say about the widespread habit of default male when it comes to animals:

This reminded me of the study about the stuffed toys I wrote about in Invisible Women:

I guess Jeremy just wasn’t sexy enough. Poor show, Jezza

OK, technically not a queue, but we’re going rogue with this newsletter

That’s it, GFPs! Until next time…stay sexy! xoxoxo